Evidence map›Paper›PMID 41951975›Full record

ArticleNature microbiology2026

Microbial 10-oxostearic acid protects mice against colitis via the nuclear receptor PPARα.

Jiabao Liu, Hao Li, Yintai Tian, Miao Guo, Cigdem Sahin, Shotaro Kamata, Akihiro Honda, Jhenielle Campbell, Jin Shi, Emine Dide Yurtal and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jiabao Liu *Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-5440-1841
Hao Li *Department of Molecular Pharmacology; Department of Genetics; Department of Medicine (Oncology); Albert Einstein College of Medicine, New York, NY, USA.
Yintai Tian *School of Pharmacy & State Key Laboratory of Natural Product Chemistry, Lanzhou University, Lanzhou, People's Republic of China.
Miao Guo *State Key Laboratory of Mechanism and Quality Research of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, People's Republic of China.
Cigdem SahinDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
Shotaro KamataLaboratory of Health Chemistry, Showa Pharmaceutical University, Machida, Japan.
Akihiro HondaLaboratory of Health Chemistry, Showa Pharmaceutical University, Machida, Japan.
Jhenielle CampbellDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Jin ShiDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
Emine Dide YurtalDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Diwen YangDepartment of Chemistry, University of Toronto, Toronto, Ontario, Canada.
Matthew JachimowiczDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada.
Shian HuSchool of Pharmacy & State Key Laboratory of Natural Product Chemistry, Lanzhou University, Lanzhou, People's Republic of China.
Yufeng GongCollege of Marine Life Sciences, Ocean University of China, Qingdao, China.
William NavarreDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-9293-9220
Isao IshiiLaboratory of Health Chemistry, Showa Pharmaceutical University, Machida, Japan.ORCID http://orcid.org/0000-0002-5367-205X
Carolyn L CumminsDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-7603-6577
Hui PengDepartment of Chemistry, University of Toronto, Toronto, Ontario, Canada. hui.peng@utoronto.ca.ORCID http://orcid.org/0000-0002-2000-1647
Shengpeng WangState Key Laboratory of Mechanism and Quality Research of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, People's Republic of China. swang@um.edu.mo.ORCID http://orcid.org/0000-0003-3575-9212
Xiaojuan WangSchool of Pharmacy & State Key Laboratory of Natural Product Chemistry, Lanzhou University, Lanzhou, People's Republic of China. xiaojuan170@outlook.com.ORCID http://orcid.org/0000-0001-5559-6997
Sridhar ManiDepartment of Molecular Pharmacology; Department of Genetics; Department of Medicine (Oncology); Albert Einstein College of Medicine, New York, NY, USA. sridhar.mani@einsteinmed.edu.ORCID http://orcid.org/0000-0003-4132-6157
Henry M KrauseDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada. h.krause@utoronto.ca.ORCID http://orcid.org/0000-0002-6182-7074

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) PJT-186117Japan Agency for Medical Research and Development (AMED) JP21am0101071National Natural Science Foundation of China (National Science Foundation of China) 82574272
6 · The paper itself

Abstract

Interactions between the host, diet and intestinal microbiota are critical for metabolic and immune homeostasis, but the intersecting metabolites and receptors remain poorly defined. Here we identify 10-oxostearic acid (10-oxoSA), a microbial metabolite derived from oleic acid, the most abundant fatty acid in nature, as a potent and selective agonist of the lipid-sensing nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα). Biochemical and structural analyses reveal that 10-oxoSA binds PPARα with higher affinity than previously identified endogenous ligands. In a mouse model of colitis, 10-oxoSA confers protection in a PPARα-dependent manner. Multi-tissue transcriptomics show that 10-oxoSA upregulates beneficial PPARα target genes in the ileum and colon, many in previously unrecognized pathways, while also circumventing deleterious hepatic responses. Multi-omics analyses also show that prolonged oral 10-oxoSA administration is well tolerated in the gut and liver with minimal impact on gut microbiota composition. These findings establish a natural diet-microbiota-host axis with potential for anti-inflammatory interventions.

Indexed as

ColitisPPAR alphaAnimalsColonDisease Models, AnimalGastrointestinal MicrobiomeLiverMaleMiceMice, Inbred C57BLPPAR alpha

Identifiers

PMID41951975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.